EA202193007A1 - Соединения пирролидина - Google Patents
Соединения пирролидинаInfo
- Publication number
- EA202193007A1 EA202193007A1 EA202193007A EA202193007A EA202193007A1 EA 202193007 A1 EA202193007 A1 EA 202193007A1 EA 202193007 A EA202193007 A EA 202193007A EA 202193007 A EA202193007 A EA 202193007A EA 202193007 A1 EA202193007 A1 EA 202193007A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- pyrrolidine compounds
- formula
- methods
- nhso2nh
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В изобретении предложены соединение формулыгде L выбран из группы, состоящей из -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, , или его фармацевтически приемлемая соль; соединения формулыспособы получения указанных соединений и их солей, фармацевтическая композиция и способы лечения пациентов, нуждающихся в таком лечении.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202193007A1 true EA202193007A1 (ru) | 2022-03-25 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202193007A EA202193007A1 (ru) | 2019-06-07 | 2020-06-03 | Соединения пирролидина |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11286249B2 (ru) |
| EP (1) | EP3980409A1 (ru) |
| JP (2) | JP6940717B2 (ru) |
| KR (3) | KR102629923B1 (ru) |
| CN (1) | CN114008021A (ru) |
| AU (1) | AU2020287599B2 (ru) |
| BR (1) | BR112021023347A2 (ru) |
| CA (1) | CA3140869A1 (ru) |
| CL (1) | CL2021003202A1 (ru) |
| CO (1) | CO2021016295A2 (ru) |
| CR (1) | CR20210602A (ru) |
| DO (1) | DOP2021000254A (ru) |
| EA (1) | EA202193007A1 (ru) |
| EC (1) | ECSP21088515A (ru) |
| IL (1) | IL288174A (ru) |
| JO (1) | JOP20210319A1 (ru) |
| MA (1) | MA56115A (ru) |
| MX (1) | MX2021014913A (ru) |
| PE (1) | PE20220134A1 (ru) |
| SG (1) | SG11202113244UA (ru) |
| WO (1) | WO2020247429A1 (ru) |
| ZA (1) | ZA202109251B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023078333A1 (zh) | 2021-11-03 | 2023-05-11 | 上海拓界生物医药科技有限公司 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
| WO2023146785A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452521A4 (en) * | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR |
| WO2005068412A1 (en) | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| AU2003300438A1 (en) | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
-
2020
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en active Application Filing
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active IP Right Grant
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 KR KR1020247002433A patent/KR20240014618A/ko active Application Filing
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 CA CA3140869A patent/CA3140869A1/en active Pending
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active IP Right Grant
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 CN CN202080041924.XA patent/CN114008021A/zh active Pending
-
2021
- 2021-09-02 JP JP2021143227A patent/JP2021191784A/ja active Pending
- 2021-11-16 IL IL288174A patent/IL288174A/en unknown
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US20220169636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021014913A (es) | 2022-01-18 |
| US11286249B2 (en) | 2022-03-29 |
| JP6940717B2 (ja) | 2021-09-29 |
| KR20230004890A (ko) | 2023-01-06 |
| DOP2021000254A (es) | 2022-01-16 |
| BR112021023347A2 (pt) | 2022-04-12 |
| ECSP21088515A (es) | 2022-01-31 |
| US20210253559A1 (en) | 2021-08-19 |
| CL2021003202A1 (es) | 2022-09-09 |
| JOP20210319A1 (ar) | 2023-01-30 |
| AU2020287599B2 (en) | 2023-10-19 |
| ZA202109251B (en) | 2024-04-24 |
| KR102629923B1 (ko) | 2024-01-30 |
| CO2021016295A2 (es) | 2021-12-10 |
| KR20220018494A (ko) | 2022-02-15 |
| EP3980409A1 (en) | 2022-04-13 |
| PE20220134A1 (es) | 2022-01-27 |
| CN114008021A (zh) | 2022-02-01 |
| JP2021524498A (ja) | 2021-09-13 |
| KR20240014618A (ko) | 2024-02-01 |
| JP2021191784A (ja) | 2021-12-16 |
| SG11202113244UA (en) | 2021-12-30 |
| CR20210602A (es) | 2022-01-06 |
| AU2020287599A1 (en) | 2022-01-06 |
| US20220169636A1 (en) | 2022-06-02 |
| WO2020247429A1 (en) | 2020-12-10 |
| IL288174A (en) | 2022-01-01 |
| CA3140869A1 (en) | 2020-12-10 |
| MA56115A (fr) | 2022-04-13 |
| KR102477481B1 (ko) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| EA201691142A1 (ru) | Ингибиторы мек и способы их применения | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| EA202090604A1 (ru) | Хроманмонобактамовые соединения для лечения бактериальных инфекций | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| EA202193007A1 (ru) | Соединения пирролидина | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA202192760A1 (ru) | Трициклические соединения | |
| EA202193211A1 (ru) | Лечение синуклеопатий | |
| EA202190458A1 (ru) | Составы, содержащие дендример | |
| EA202190689A1 (ru) | Производные хинолина в качестве ингибиторов интегрина альфа4бета7 | |
| EA202192382A1 (ru) | Соединения, нацеленные на prmt5 | |
| EA201991008A1 (ru) | Новые производные нафтиридинона и их применение в лечении аритмии |